P
Patricia K. Nguyen
Researcher at Stanford University
Publications - 82
Citations - 3963
Patricia K. Nguyen is an academic researcher from Stanford University. The author has contributed to research in topics: Stem cell & Coronary artery disease. The author has an hindex of 26, co-authored 77 publications receiving 3363 citations. Previous affiliations of Patricia K. Nguyen include VA Palo Alto Healthcare System & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells
Feng Lan,Andrew S. Lee,Ping Liang,Veronica Sanchez-Freire,Patricia K. Nguyen,Li Wang,Leng Han,Michelle Yen,Yongming Wang,Ning Sun,Oscar J. Abilez,Shijun Hu,Antje D. Ebert,Enrique G. Navarrete,Chelsey S. Simmons,Matthew T. Wheeler,Beth L. Pruitt,Richard S. Lewis,Yoshinori Yamaguchi,Euan A. Ashley,Donald M. Bers,Robert C. Robbins,Michael T. Longaker,Joseph C. Wu +23 more
TL;DR: Patients generating patient-specific induced pluripotent stem cell cardiomyocytes from a ten-member family cohort carrying a hereditary HCM missense mutation (Arg663His) in the MYH7 gene are generated to help elucidate the mechanisms underlying HCM development and identify novel therapies for the disease.
Journal ArticleDOI
Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity
Ping Liang,Feng Lan,Andrew S. Lee,Tingyu Gong,Veronica Sanchez-Freire,Yongming Wang,Sebastian Diecke,Karim Sallam,Joshua W. Knowles,Paul J. Wang,Patricia K. Nguyen,Donald M. Bers,Robert C. Robbins,Joseph C. Wu +13 more
TL;DR: The data indicate that healthy and diseased individuals exhibit different susceptibilities to cardiotoxic drugs and that use of disease-specific hiPSC-CMs may predict adverse drug responses more accurately than the standard human ether-a-go-go–related gene test or healthy control hiPSc-CM/hESC-CM screening assays.
Journal ArticleDOI
Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review.
TL;DR: Although stem cell therapy for cardiovascular disease is not yet ready for routine clinical application, significant progress continues to be made and Physicians should be aware of the current status of this treatment so they can better inform their patients who may be in search of alternative therapies.
Journal ArticleDOI
Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion Imaging: Integrated ADVANCE-MPI Trial Results
Manuel D. Cerqueira,Patricia K. Nguyen,Peter Staehr,S. Richard Underwood,Ami E. Iskandrian,Advance-Mpi Trial Investigators +5 more
TL;DR: Regadenoson can be safely administered as a fixed unit bolus and is as efficacious as adenosine in detecting ischemia regardless of age, gender, body mass index, and diabetes.
Journal ArticleDOI
Stem cell imaging: from bench to bedside
TL;DR: How in vivo molecular imaging has helped identify barriers to clinical translation and potential strategies that may contribute to successful transplantation and improved outcomes is discussed, with a focus on cardiovascular and neurological diseases.